AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

PsyBio Therapeutics Corp

$0 +$0.00 (+0.00%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0
Day Range
$0$0.01
Year Range
$0$0.01
Market Cap
1.27K
AVG Volume
6.95K
Trailing/Forward PE
-0/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Net Income (USD) · TTM
-15M-10M-5M021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
PSYBF Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
23 Q2-2.86M
23 Q1-4.11M
22 Q4-4.89M
22 Q3-6.39M
22 Q2-7.77M
22 Q1-10.17M
21 Q4-11.16M
21 Q3-8.8M
21 Q2-7.15M
21 Q1-3.31M
Operating Income (USD) · TTM
-10M-7.5M-5M-2.5M021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
PSYBF Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
23 Q2-2.74M
23 Q1-3.98M
22 Q4-4.75M
22 Q3-6.06M
22 Q2-7.47M
22 Q1-9.9M
21 Q4-9.8M
21 Q3-7.48M
21 Q2-5.8M
21 Q1-6.2M
EBITDA (USD) · TTM
-10M-7.5M-5M-2.5M021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
PSYBF EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
23 Q2-2.71M
23 Q1-3.94M
22 Q4-4.71M
22 Q3-5.85M
22 Q2-7.29M
22 Q1-9.73M
21 Q4-9.59M
21 Q3-7.49M
21 Q2-5.16M
21 Q1-1.36M
Cash Flows (USD) · TTM
-8M-6M-4M-2M021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
PSYBF Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
23 Q2-889.77K
23 Q1-2.53M
22 Q4-3.44M
22 Q3-5.59M
22 Q2-6.31M
22 Q1-7.5M
21 Q4-6.95M
21 Q3-4.67M
21 Q2-3.24M
21 Q1-739.83K
EPS (USD) · TTM
-0.15-0.1-0.05-021 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
PSYBF EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
23 Q2-0.03
23 Q1-0.04
22 Q4-0.05
22 Q3-0.05
22 Q2-0.07
22 Q1-0.09
21 Q4-0.11
21 Q3-0.09
21 Q2-0.08
21 Q1-0.04
Expenses (USD) · TTM
02.5M5M7.5M10MR&DSG&A21 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
PSYBF Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
23 Q22.51M
23 Q13.66M
22 Q44.29M
22 Q35.62M
22 Q27.08M
22 Q19.62M
21 Q49.67M
21 Q37.5M
21 Q25.61M
21 Q11.81M
Shares Outstanding (USD) · TTM
-3M-2M-1M01MBuybacks (Repurchases)Stock-Based Compensation21 Q121 Q221 Q321 Q422 Q122 Q222 Q322 Q423 Q123 Q2
PSYBF Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
23 Q2-299.47K
23 Q1-371.28K
22 Q4-420.6K
22 Q3-828.9K
22 Q2-1.38M
22 Q1-2.12M
21 Q4-2.13M
21 Q3-1.72M
21 Q2-1.1M
21 Q1-284.23K
Free Cash Flow Yield
-800000%-600000%-400000%-200000%0%med -6941.75%Jan 25May 25Sep 25Jan 26May 26Sep 26
PSYBF Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-69417.52%
Sep 26-69417.52%
Aug 26-69417.52%
Aug 26-69417.52%
Aug 26-69417.52%
Aug 26-69417.52%
Jul 26-69417.52%
Jul 26-69417.52%
Jul 26-694175.2%
Jul 26-69417.52%
Jul 26-69417.52%
Jun 26-69417.52%
Jun 26-69417.52%
Jun 26-69417.52%
Jun 26-69417.52%
May 26-69417.52%
May 26-69417.52%
May 26-69417.52%
May 26-694175.2%
May 26-69417.52%
Apr 26-69417.52%
Apr 26-69417.52%
Apr 26-69417.52%
Apr 26-69417.52%
Mar 26-69417.52%
Mar 26-69417.52%
Mar 26-69417.52%
Mar 26-69417.52%
Feb 26-69417.52%
Feb 26-69417.52%
Feb 26-69417.52%
Feb 26-69417.52%
Jan 26-69417.52%
Jan 26-69417.52%
Jan 26-69417.52%
Jan 26-69417.52%
Jan 26-69417.52%
Dec 25-69417.52%
Dec 25-69417.52%
Dec 25-69417.52%
Dec 25-69417.52%
Nov 25-69417.52%
Nov 25-69417.52%
Nov 25-69417.52%
Nov 25-6941.75%
Oct 25-6941.75%
Oct 25-6941.75%
Oct 25-6941.75%
Oct 25-6941.75%
Oct 25-6941.75%
Sep 25-6941.75%
Sep 25-6941.75%
Sep 25-6941.75%
Sep 25-6941.75%
Aug 25-6941.75%
Aug 25-6941.75%
Aug 25-6941.75%
Aug 25-6941.75%
Aug 25-6941.75%
Jul 25-6941.75%
Jul 25-6941.75%
Jul 25-6941.75%
Jul 25-6941.75%
Jun 25-6941.75%
Jun 25-6941.75%
Jun 25-6941.75%
Jun 25-6941.75%
May 25-6941.75%
May 25-6941.75%
May 25-6941.75%
May 25-6941.75%
May 25-6941.75%
Apr 25-6941.75%
Apr 25-6941.75%
Apr 25-6941.75%
Apr 25-6941.75%
Mar 25-69417.52%
Mar 25-6941.75%
Mar 25-6941.75%
Mar 25-6941.75%
Feb 25-6941.75%
Feb 25-6941.75%
Feb 25-6941.75%
Feb 25-6941.75%
Jan 25-6941.75%
Jan 25-6941.75%
Jan 25-694175.2%
Jan 25-6941.75%
Jan 25-6941.75%
Dec 24-6941.75%
Dec 24-6941.75%
Dec 24-6941.75%
Dec 24-6941.75%
Nov 24-6941.75%
Nov 24-6941.75%
Nov 24-6941.75%
Nov 24-6941.75%
Nov 24-138.84%
Oct 24-138.84%
Oct 24-138.84%
EV/EBITDA
200250300350400450med 305.12Apr 21May 21May 21Jun 21Jun 21
PSYBF EV/EBITDA by quarter
PeriodEV/EBITDA
Jun 21381.96
Jun 21418.18
Jun 21425.24
Jun 21356.39
May 21281.68
May 21244.12
May 21241.63
May 21262.95
Apr 21304.34
Apr 21305.9
Price to Book
0100200300400med 3.78Aug 21Oct 21Jan 22Apr 22Jul 22Sep 22Dec 22
PSYBF Price to Book by quarter
PeriodPrice to Book
Dec 22120.78
Dec 22141.22
Dec 22168.1
Dec 22202.18
Nov 22166.02
Nov 22189.3
Nov 22216.94
Nov 22189.3
Oct 22227.16
Oct 22213.91
Oct 22285.85
Oct 22351.72
Sep 22357.59
Sep 2210.91
Sep 229.33
Sep 2211.26
Sep 2210.98
Aug 229.08
Aug 227.24
Aug 226.33
Aug 224.79
Jul 225.07
Jul 222.85
Jul 224.46
Jul 226.28
Jul 226.17
Jun 224.04
Jun 222.68
Jun 222.34
Jun 222.43
May 222.02
May 222.11
May 222.2
May 223.42
Apr 223.16
Apr 223.33
Apr 223.09
Apr 223.04
Apr 223.76
Mar 222.36
Mar 222.78
Mar 222.8
Mar 222.95
Feb 223.23
Feb 222.86
Feb 223.31
Feb 223.4
Jan 223.66
Jan 223.78
Jan 224.11
Jan 224.42
Dec 213.78
Dec 213.28
Dec 213.3
Dec 213.21
Dec 214.63
Nov 214.67
Nov 215.36
Nov 215.42
Nov 215.75
Oct 215.59
Oct 214.31
Oct 214.48
Oct 214.42
Oct 213.98
Sep 212.54
Sep 212.64
Sep 212.94
Sep 213.17
Aug 213.21
Aug 213.01
Aug 213.39
Aug 212.8
Jul 212.83
Jul 212.92
Jul 213.2
Jul 213.4
Jul 213.63
PsyBio Therapeutics Corp
PSYBF
Stockpicker

Video analysis: PSYBF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.